

CURRICULUM VITAE FOR

DR BEN TURNER

Consultant and Honorary Senior Lecturer in Neurology
Barts Health NHS Trust &
Queen Mary's University London

Education	St Mary's Hospital Medical School, London St Paul's School, Barnes, London
Qualifications	DM 2003 MRCP 1996 MBBS 1991
Membership	GMC 3591284 MDU 270730G FRCP Association of British Neurologists British Medical Association

Key Skills and Achievements:

Clinical Training

I performed my general medical training in London, Newcastle and Sunderland where I gained experience in General Medical emergencies and specialities, including respiratory, endocrinology, cardiology and nephrology. I worked in Ophthalmology at Sunderland Eye Infirmary for 12 months.

I was a senior SHO in Neurology at Sheffield for one year and then Neurology research fellow at Nottingham University Hospital for two years. I trained as a Neurology SpR for 4 years at QMC, Nottingham and its attached Hospitals. In this time I had excellent training in the full range of neurological conditions and their management.

I was Locum Consultant Neurologist at QMC, Nottingham from November 2002 to April 2003, with a particular view to instigating the Risk Sharing Scheme for MS.

I was appointed Consultant Neurologist at The Royal London in 2003, I was clinical lead for Neurology from 2010 to 2014, and 2018 to 2020.. I have maintained CPD throughout, completing appraisal and revalidation.

Education and Audit

Elected as the Secretary for the Association of British Neurologist (ABN) Trainees and thereby sat, as the trainees observer, on the Royal College of Physicians Specialist Advisory Committee in Neurology and the ABN Training and Education Subcommittee (TESC). This has given me a privileged insight into the strengths and weaknesses of neurological training. I helped develop a curriculum and assessment tools robust and transparent enough to satisfy the STA and JCHMT.

Returning to this field in 2017 I became Training Programme Director for Neurology and Stroke Juniors at Barts Health. I am an Educational Supervisor, I participate in ARCP assessments, HEE NTN interviews and appointments and Neurology Training Programme Management Committee.

I perform regular clinical teaching for medical students.

I lecture at the Barts MS preceptorship, teach on London Calman day teaching and give regular lectures to GP's, and at MS speciality meetings.

Research

In July of 2003 I was awarded my MD for my thesis 'Brain atrophy in multiple sclerosis'. This involved the development of a novel image analysis methods to estimate the volume change on magnetic resonance images and the application of these techniques multiple sclerosis patients and controls. This has resulted in three peer review articles. I collaborated with my neurosurgical colleagues and applied methods of ventricular measurement to study the outcome of different surgical procedures for

hydrocephalus. I am interested in the neurological implications of Coeliac disease and have investigated patients with dermatitis herpetiformis for evidence of neurological disease and immunological markers, resulting in a peer review publication.

Whilst a research registrar I participated in several multi-national, multi-centre randomised placebo controlled trials, organising the trials locally and recruiting patients in Nottingham.

At The Royal London I continue to run clinical trials for patients with MS and I was the UK Chief Investigator and Principle Investigator for over 6 MS studies.

As Honorary Senior Lecturer at QMUL I continue to have active interest in research, actively doing research in MS and contributing to publications, varying from tuberculosis meningitis to dietary causes of MS.

Appointments

Current Appointment

Consultant Neurologist and Honorary Senior Lecturer, Barts Health NHS Trust.

Previous Appointments

Locum Consultant	Queen's Medical Centre, November 2002-April 2003
SpR Training	University Hospital, Queen's Medical Centre, Nottingham, January 1999 – November 2002
Research	Neurology research registrar January 1997-January 1999 University of Nottingham, Nottingham Supervisor: Professor L D Blumhardt / Dr CS Constantinescu
Neurology	Senior House Officer February 1996-December 1996 Royal Hallamshire Hospital, Sheffield Consultants: Professor H J Sagar/Dr G A B Davies-Jones/Dr G S Venables/Dr S J L Howell/Dr R A Grunewald
Ophthalmology	Senior House Officer August 1995-February 1996 Eye Infirmary, Sunderland
Rheumatology/ General Medicine	Senior House Officer March 1995-July 1995 Freeman Hospital, Newcastle
Neurology	Senior House Officer February 1995-March 1995 Newcastle General Hospital Consultants: Dr P Hudgson/Dr T Walls
Neurology/	Senior House Officer August 1994-February 1995

General Medicine	District General Hospital, Sunderland Consultants: Dr P G Cleland/Dr R E Jones
Nephrology/ General Medicine	Senior House Officer February 1994- July 1994 Royal Infirmary, Sunderland
Respiratory/ General Medicine	Senior House Officer August 1993- January 1994 Royal Infirmary, Sunderland
Accident and Emergency	Senior House Officer February 1993- July 1993 Central Middlesex Hospital, London
General Surgery/ Cardiothoracic	House Officer February 1992- August 1992 St Mary's Hospital, London
General Medicine	House Office August 1991- February 1992 Hillingdon Hospital, Middlesex, London

Publications

Dayan M, Turner B, McGhee C. Acute angle closure glaucoma masquerading as systemic illness. **BMJ** 1996; 313(7054): 413-5.

Turner B, Wills AJ. Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. **J Neurol Neurosurg Psychiatry** 2000; 68: 790-1.

Tattersall R, Turner B. Brown-Sequard and his syndrome. **Lancet** 2000; 356: 61-3.

Turner B, Wills AJ. Intravenous immunoglobulin causing reversible post-leukoencephalopathy syndrome? **J Neurol Neurosurg Psychiatry** 2000; 69: 704.

Turner B, Ramli N, Jaspan T, Blumhardt LD. Ventricular enlargement in multiple sclerosis: a comparison of linear and three dimensional MRI estimates. **Neuroradiology** 2001; 43(8): 608-14.

Wilson M, Morgan PS, Lin X, Turner B, Blumhardt LD. Quantitative diffusion weighted magnetic resonance imaging, cerebral atrophy and disability in multiple sclerosis. **J Neurol Neurosurg Psychiatry** 2001; 70: 318-22.

Wills AJ, Turner B, Unsworth J, Fry L. Dermatitis herpetiformis, coeliac disease and neurological dysfunction. **J Neurol Neurosurg Psychiatry** 2001; 72(2): 259-261.

Buxton N, Turner B, Ramli N, Vloeberghs M. Changes in third ventricular size with neuroendoscopic third ventriculostomy: a blinded study. **J Neurol Neurosurg Psychiatry** 2001; 72(3): 385-7.

Turner B, Wills AJ. Superficial siderosis associated with anterior horn cell dysfunction. **J Neurol Neurosurg Psychiatry** 2002; 72(2): 274-5

Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over 4 years. **Multiple Sclerosis** 2003; 9: 21-7.

Lin X, Tench C R, Turner B, Blumhardt L D, Constantinescu C S. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β -1a (Rebif) treatment trial. **J Neurol Neurosurg Psychiatry** 2003; 74: 1090-1094.

Everett C M, Dhillon H, Samarasinghe D, Berry L, Warwick S, Turner B. A Case of Cerebral Nocardiosis Following Brief Immunosuppression. **European Journal of Neurology** 2006;13: 423 – 432

Schmierer K, Turner BP. The second revision of ‘McDonald’ criteria for the diagnosis of multiple sclerosis. **ACNR** 2012;12[suppl]:3-4.

R Dobson, A Davis, B Turner. Multiple Sclerosis: Visual Guide for Clinicians. Chapter: Diagnosing Multiple Sclerosis –**Clinical Publishing Oxford** 2013

Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G. Assessing treatment response to interferon- β . **Neurology** 2014;82(3):248-254.

Turner B, Bauer D, Benamor M, Truffinet P, Miller A. Teriflunomide in Early Stage MS: Results from TOPIC. **ABN** May 2014

Schmierer K, Marta M, Turner B, Giovannoni G. The use of MRI in the management of multiple sclerosis in the UK. **ABN** 2014

Su L, Smith P, Beavan M, Schmierer K, Turner B. Comparison of 2005 and 2010 Macdonald MRI criteria for diagnosis of MS: a retrospective study in London, **EFNS** 2014

Dimitrov L, Turner B. Oral Therapies in Relapsing Remitting MS. **ACNR** 2015; 14 (3-5)

Renukanthan A, Quinton R, Turner B, MacCallum P, Seal L, Davies A, Green R, Evanson J, Korbonits M. Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia. **Endocrine**. 2015 Nov;50(2):496-503. doi: 10.1007/s12020-015-0562-5. Epub 2015 Mar 5.

Raciborska D, Giovannoni G, Schmierer K, Turner B. Barts MS Fingolimod Audit. **EAN** 2015

B. Turner, T. Vollmer, E. Havrdova, S. Lynch, S. Wray, C. Ford, P. Wang, Y. Liu, J. Elkins, L. Barbato. Daclizumab HYP reduced psychological impact of multiple sclerosis versus intramuscular interferon beta-1a in the DECIDE trial
ECTRIMS Oct 8, 2015; 115563 Abstract: P685

Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? **Mult Scler Relat Disord** 2015;4:329-33.

Pakpoor, J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. **Neurol Neuroimmunol Neuroinflamm** 2015;2:e158.

Giovannoni G¹, Marta M¹, Davis A¹, Turner B¹, Gnanapavan S¹, Schmierer K¹.
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. **Pract Neurol**. 2016 Oct;16(5):389-93. doi: 10.1136/practneurol-2015-001355. Epub 2016 Apr 25.

Campion T, Smith RJP, Altmann DR, Turner BP, Evanson J, George IC, Sati P, Reich DS, Miquel ME, Schmierer K.

FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis? **Eur Radiol**. 2017 Oct;27(10):4257-4263. doi: 10.1007/s00330-017-4822-z. Epub 2017 Apr 13.

Albor C, du Sautoy T, Kali Vanan N, Turner BP, Boomla K, Schmierer K.

Ethnicity and prevalence of multiple sclerosis in East London,

Mult Scler. 2017 Jan;23(1):36-42. doi: 10.1177/1352458516638746. Epub 2016 Jul 11.

Shah AM, Raciborska D, Stevens M, Gnanapavan S, White VLC, Turner B
Tuberculous tales: an East London experience. **Pract Neurol**. 2017 Dec;17(6):429-438. doi:
10.1136/practneurol-2017-001653. Epub 2017 Aug 17.

O. Yildiz, D. Raciborska, A. Stennett, **B. Turner**, G. Giovannoni, K. Schmierer
Systematic multidimensional clinical point-of-care monitoring of people with multiple
sclerosis using 3-test. **ECTRIMS** Oct 12 2018 228873 Abstract: P1031

Sariqa Wagley, Monika Bokori-Brown, Helen Morcrette, Andrea Malaspina,
Caroline D'Arcy, Sharmilee Gnanapavan, Nicholas Lewis, Michel R Popoff,
Dominika Raciborska, Richard Nicholas, **Ben Turner** and Richard W Titball
Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.

Banerjee G, Adams ME, Jaunmuktane Z, Alistair Lammie G, **Turner B**, Wani M, Sawhney
IMS, Houlden H, Mead S, Brandner S, Werring DJ.
Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura.
Ann Neurol. 2019 Feb;85(2):284-290. doi: 10.1002/ana.25407. Epub 2019 Jan 17.

B Turner, BAC Cree, L Kappos, X Montalban, Stephen L. Hauser
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Journal of Neurology February 2019 DOI: 10.1007/s00415-019-09248-6